Trade Nektar Therapeutics - NKTR stock price

71.15
-0.02%
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration

NKTR price history

Date Close Change Chg% Open Min. Max.
2022-09-30 70.23 1.51 2.20 68.72 68.72 70.83
2022-09-30 70.93 1.56 2.25 69.37 68.99 72.37
2022-09-30 70.32 1.21 1.75 69.11 67.02 71.39
2022-09-30 70.03 -0.92 -1.30 70.95 67.96 71.58
2022-09-30 70.59 1.81 2.63 68.78 68.78 73.25
2022-09-30 70.56 -2.40 -3.29 72.96 69.16 72.96
2022-09-30 68.88 1.00 1.47 67.88 67.11 69.53
2022-09-30 69.03 0.07 0.10 68.96 67.88 70.55
2022-09-30 68.0 3.85 6.00 64.15 63.67 68.43
2022-09-30 64.6 -0.44 -0.68 65.04 64.24 68.15
2022-09-30 67.97 3.35 5.18 64.62 64.62 68.31
2022-09-30 66.89 0.19 0.28 66.7 65.43 68.11
2022-09-30 68.13 1.51 2.27 66.62 64.05 68.37
2022-09-30 66.95 -0.67 -0.99 67.62 66.63 68.98
2022-09-30 68.1 -0.60 -0.87 68.7 66.62 69.43

Mobile app

Full trading account functionality: order execution and cancellation, stop-loss and take-profit setup, transaction history, deposits and withdrawals

iOS
4,7
12 127 reviews
Android
4,1
9 795 reviews
Go help.dzengi.com
Dzengi Exchange
Trade BTC & tokenized stocks